FibroGen shares are trading higher after the company announced announced that the FDA cleared its Investigational New Drug of FG-3165. Also, the company announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FG-3165 and FG-3175 in combination with LIBTAYO.
Portfolio Pulse from Benzinga Newsdesk
FibroGen shares are trading higher after the company announced that the FDA cleared its Investigational New Drug FG-3165. Additionally, FibroGen has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FG-3165 and FG-3175 in combination with LIBTAYO.
June 03, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FibroGen shares are trading higher following FDA clearance of FG-3165 and a new clinical trial supply agreement with Regeneron Pharmaceuticals.
The FDA clearance of FG-3165 is a significant regulatory milestone, likely boosting investor confidence. The partnership with Regeneron for clinical trials further enhances the potential for successful outcomes, driving the stock price higher.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Regeneron Pharmaceuticals is involved in a new clinical trial supply agreement with FibroGen to evaluate FG-3165 and FG-3175 in combination with LIBTAYO.
The clinical trial supply agreement with FibroGen could lead to new treatment combinations involving LIBTAYO, potentially expanding Regeneron's product offerings and market reach.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50